Given the important role of AEC mtDNA damage in promoting mitochondria-regulated apoptosis and subsequent pulmonary fibrosis, we reason that strategies aimed at augmenting lung SIRT3 levels are an innovative therapeutic target for managing patients with IPF and other forms of lung fibrosis. This evidence concerns the gene SIRT3 and pulmonary fibrosis.